摘要
目的研究慢性乙肝(CHB)患者阿德福韦酯治疗前后及HBV携带者CD8+T细胞表面活化分子CD38和HLA-DR表达情况,并探讨其与疾病进展的关系。方法收集32例经阿德福韦酯治疗的CHB患者,31例HBV携带者和28例正常对照,采集CHB患者治疗前后及HBV携带者和正常对照外周血。采用流式细胞术检测CD4+和CD8+T细胞数量和比例,以及CD8+CD38+和CD8+HLA-DR+T细胞比例,HBV DNA和生化由本院检验室检测。结果 CHB患者治疗前CD8+CD38+T细胞比例显著高于HBV携带者和正常对照组,阿德福韦酯治疗后显著降低(P<0.05)。HBV携带者CD8+CD38+T细胞比例高于正常对照组(P<0.05)。CHB患者治疗前CD8+HLA-DR+T细胞比例显著高于正常对照组(P<0.01),但与HBV携带者无明显差异,阿德福韦酯治疗后显著下降,仍高于正常水平(P<0.05)。结论 HBV感染可以引起CD8+T活化水平显著升高,阿德福韦酯抗病毒治疗能够降低CD8+T的活化。CD8+T活化水平是良好的HBV感染病情评价指标。
Objective To determine the expression of CD38 and HLA-DR on CD8 ＋T cells in patients with chronic hepatitis B and HBV carriers, and the relation between immune activation and disease progression of HBV infection.Methods Thirty-two chronic hepatitis B patients receiving adefovir dipivoxil treatment, 31 HBV carriers and 28 normal controls were collected. The counts of CD4＋and CD8＋T cells and the percentage of CD8＋CD38＋and CD8＋HLA-DR ＋ T cells were tested by flow cytometry. HBVDNA and liver function were tested in the central laboratory of our hospital. Results The percentage of CD8＋CD38＋T cells in CHB patients was increased and higher than in HBV carriers and normal controls, and decreased after adefovir dipivoxil treatment（P0.05）. The percentage of CD8＋CD38＋T cells in HBV carriers was much higher than in normal controls（P0.05）. The percentage of CD8＋HLA-DR＋ T cells in CHB patients was higher than in normal controls, but similar to that in HBV carriers. CD8＋HLA-DR＋ T cells in CHB patients also decreased after adefovir dipivoxil treatment（P0.05）. Conclusion Our study demonstrates that activation of CD8＋T cells is increased in HBV infection but decreased by adefovir dipivoxil treatment. The percentages of CD8＋CD38＋and CD8＋HLA-DR＋ T are good markers for disease progression of HBV infection.
出处
《中国现代医生》
2014年第34期14-17,共4页
China Modern Doctor
基金
浙江省中医药科技计划(2010ZB160)
